CN116570679A - Blood sugar reducing and heart soothing formula applied to diabetic myocardial injury - Google Patents
Blood sugar reducing and heart soothing formula applied to diabetic myocardial injury Download PDFInfo
- Publication number
- CN116570679A CN116570679A CN202310448739.8A CN202310448739A CN116570679A CN 116570679 A CN116570679 A CN 116570679A CN 202310448739 A CN202310448739 A CN 202310448739A CN 116570679 A CN116570679 A CN 116570679A
- Authority
- CN
- China
- Prior art keywords
- heart
- myocardial injury
- radix
- hypoglycemic
- soothing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 30
- 208000037891 myocardial injury Diseases 0.000 title claims abstract description 26
- 239000008280 blood Substances 0.000 title description 24
- 210000004369 blood Anatomy 0.000 title description 24
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 15
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 15
- 241000270666 Testudines Species 0.000 claims abstract description 15
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 15
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 14
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 14
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 14
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 14
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 14
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract description 14
- 244000299790 Rheum rhabarbarum Species 0.000 claims abstract description 14
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 14
- 235000005412 red sage Nutrition 0.000 claims abstract description 14
- 241001061264 Astragalus Species 0.000 claims abstract description 12
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 12
- 235000006533 astragalus Nutrition 0.000 claims abstract description 12
- 210000004233 talus Anatomy 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 7
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 6
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 6
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 4
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 4
- 240000006766 Cornus mas Species 0.000 claims abstract 5
- 239000000463 material Substances 0.000 claims description 20
- 241000208340 Araliaceae Species 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 235000021028 berry Nutrition 0.000 claims description 9
- 238000000227 grinding Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 241000405414 Rehmannia Species 0.000 claims description 7
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000004576 sand Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000004217 heart function Effects 0.000 abstract description 7
- 206010067484 Adverse reaction Diseases 0.000 abstract description 6
- 230000006838 adverse reaction Effects 0.000 abstract description 6
- 230000037149 energy metabolism Effects 0.000 abstract description 4
- 210000004165 myocardium Anatomy 0.000 abstract 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 26
- 230000001737 promoting effect Effects 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 11
- 241000209020 Cornus Species 0.000 description 10
- 230000002107 myocardial effect Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 229940126673 western medicines Drugs 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 241000218202 Coptis Species 0.000 description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000008721 basement membrane thickening Effects 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000009877 shengmai Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application discloses a hypoglycemic heart-soothing formula applied to diabetic myocardial injury in the field of medicine, which comprises the following components in parts by weight: 10-20g of turtle shell, 10-20g of ginseng, 10-20g of astragalus, 10-20g of dwarf lilyturf tuber, 15-25g of dogwood, 10-20g of radix rehmanniae, 10-20g of rhubarb, 5-15g of coptis chinensis, 20-30g of red sage root, 7-17g of peach kernel, 10-20g of tree peony bark, 15-25g of Chinese yam and 5-15g of Chinese magnoliavine fruit. The application not only regulates the energy metabolism of cardiac muscle and improves the reconstruction of cardiac muscle, thereby improving cardiac function, but also has no obvious adverse reaction and better safety.
Description
Technical Field
The application belongs to the field of medicines, and in particular relates to a hypoglycemic heart-soothing formula applied to diabetic myocardial injury.
Background
Diabetic cardiomyopathy is considered to be a primary myocardial injury that occurs in diabetics and is independent of coronary artery disease and hypertension. At present, the research shows that the heart structure and function of a diabetic patient are obviously changed without myocardial ischemia and hypertension, and the diabetic patient has the pathological characteristics of myocardial cell hypertrophy, interstitial fibrosis, PAS positive substance infiltration, coronary arteriolar basement membrane thickening, myocardial internal microangiopathy and the like. Clinically manifested as left ventricular diastolic and/or systolic dysfunction, or with heart failure, cardiogenic shock, or even sudden death. Diabetic cardiomyopathy can cause the heart function of a patient to be reduced, and finally cause serious arrhythmia and heart failure, and the life quality and the life span of the patient are obviously reduced. Therefore, the basic research of the diabetic myocardial injury has become the leading edge and hot spot of the field of 'diabetic heart pathology', and the effective prevention and treatment of the diabetic myocardial injury is also one of important targets of clinical medical treatment. However, until now, researchers have not fully understood the pathophysiological mechanisms of diabetic myocardial injury, and clinically lack effective strategies and measures for the prevention and treatment of diabetic myocardial injury.
At present, no specific treatment method exists, and the following treatment measures can be adopted: 1. controlling blood sugar; although it is not clear whether strict glycemic control alters the course of diabetic cardiomyopathy, hyperglycemia should be controlled timely and effectively; 2. lowering blood pressure; the treatment of hypertension is a basic therapeutic measure, and ideal antihypertensive drugs include angiotensin converting enzyme inhibitors, calcium channel blockers and alpha 1-receptor blockers; 3. reducing blood lipid; diabetes patients have a higher probability of hyperlipidemia than normal people, so that blood lipid lowering treatment is sometimes required; 4. anti-heart failure treatment; 5. treating angina pectoris.
Although western medicines show extremely high curative effects in the aspect of treating certain myocardial injuries, in actual use, some western medicines can cause burden to organs such as liver, kidney and the like of a patient, and some western medicines have toxicity and dependence, and long-term use of certain western medicines can possibly cause increased drug tolerance, so that the originally effective drugs gradually lose curative effects. The application provides a hypoglycemic heart-soothing formula applied to diabetic myocardial injury, so as to solve the problems.
Disclosure of Invention
The application provides a hypoglycemic heart-soothing formula applied to diabetic myocardial injury, which not only regulates myocardial energy metabolism and improves myocardial reconstruction, thereby improving cardiac function, but also has no obvious adverse reaction and better safety.
In order to achieve the above object, the technical scheme of the present application is as follows: a hypoglycemic heart-soothing formula applied to diabetic myocardial injury comprises the following components in parts by weight: 10-20g of turtle shell, 10-20g of ginseng, 10-20g of astragalus root, 10-20g of dwarf lilyturf tuber, 15-25g of dogwood, 10-20g of dried rehmannia root, 10-20g of rhubarb, 5-15g of coptis root, 20-30g of red sage root, 7-17g of peach kernel, 10-20g of tree peony bark, 15-25g of Chinese yam and 5-15g of Chinese magnoliavine fruit 。
Further, the composition by weight of the composition is as follows: 10g of turtle shell, 10g of ginseng, 10g of astragalus, 10g of dwarf lilyturf tuber, 15g of dogwood, 10g of radix rehmanniae, 10g of rhubarb, 5g of coptis chinensis, 20g of red sage root, 7g of peach kernel, 10g of moutan bark, 15g of Chinese yam and 5g of shizandra berry.
Further, the composition by weight of the composition is as follows: 15g of turtle shell, 15g of ginseng, 15g of astragalus, 15g of dwarf lilyturf tuber, 20g of dogwood, 15g of dried rehmannia root, 15g of rhubarb, 10g of coptis chinensis, 25g of red sage root, 12g of peach kernel, 15g of moutan bark, 20g of Chinese yam and 10g of shizandra berry.
Further, the composition by weight of the composition is as follows: 20g of turtle shell, 20g of ginseng, 20g of astragalus, 20g of dwarf lilyturf tuber, 25g of dogwood, 20g of dried rehmannia root, 20g of rhubarb, 15g of coptis chinensis, 30g of red sage root, 17g of peach kernel, 20g of moutan bark, 25g of Chinese yam and 15g of shizandra berry.
Further, it is made by the following method:
step one: selecting materials, selecting mud sand and foreign matters of the medicinal materials, and weighing the medicinal materials according to any weight of the examples 1-4;
step two: grinding all the medicinal materials respectively;
step three: mixing the medicinal material powder ground in the second step, and uniformly stirring;
step four: sterilizing, wherein radiation sterilization is used for carrying out radiation sterilization on all the prepared medicines to be packaged.
Further, the grinding medicinal materials in the step are as follows: extracting carapax Trionycis, corni fructus, radix rehmanniae, saviae Miltiorrhizae radix, semen Persicae, cortex moutan and rhizoma Dioscoreae with water, and making into extract fine powder; grinding Ginseng radix, radix astragali, radix Ophiopogonis, radix et rhizoma Rhei, coptidis rhizoma and fructus Schisandrae respectively into fine powder.
In the formula, the Chinese herbal medicines for reducing blood sugar and soothing heart applied to the diabetic myocardial injury have the following effects:
turtle shell: has effects in nourishing yin, invigorating kidney, stopping bleeding, promoting granulation, caring skin, tranquilizing mind, and treating frequent nocturia due to kidney yin deficiency.
Ginseng: has effects of invigorating qi, strengthening exterior, tonifying yang, promoting salivation, quenching thirst, refreshing brain, and enhancing disease resistance.
Radix astragali: has effects of invigorating spleen and strengthening spleen, invigorating yang, relieving sinking, invigorating and consolidating superficial resistance, promoting urination, removing toxic substances, and promoting granulation, and can be used for treating spleen qi deficiency, lung qi deficiency, spontaneous perspiration due to qi deficiency, and skin and external diseases.
Radix Ophiopogonis: has effects of nourishing yin, promoting salivation, relieving restlessness, tranquilizing mind, moistening lung, and clearing heart fire, and can be used for treating vexation, palpitation, etc. due to heart yin deficiency and heat.
Fructus Corni: has effects of invigorating liver and kidney, astringing, and can be used for invigorating kidney essence and tonifying kidney yang.
Radix rehmanniae: has effects of nourishing yin, invigorating kidney, clearing heat, removing dampness, nourishing blood, tranquillizing mind, nourishing yin, and moistening dryness, and can be used for treating insomnia, amnesia, palpitation, etc.
Rhubarb: has effects of purging heat, removing intestinal stasis, cooling blood, removing toxic substances, removing blood stasis, and dredging channels, and can be used for treating constipation due to excessive heat accumulation, hematemesis, epistaxis, conjunctival congestion, swelling and pain, blood stasis, amenorrhea, puerperal stagnation, etc.
Coptis root: has effects of clearing heat and detoxicating, suppressing hyperactive liver and clearing heat, invigorating stomach and lowering fire, and resisting bacteria and inflammation, and can be used for treating oral ulcer, acute intestine and stomach, excessive liver fire and hemorrhage etc.
Root of red-rooted salvia: has effects of promoting blood circulation, removing blood stasis, dredging channels, relieving pain, clearing heart fire, relieving restlessness, cooling blood, and resolving carbuncle, and can be used for treating chest pain, pain in chest, abdomen, hypochondrium, abdominal mass, pain due to pyretic arthralgia, vexation, insomnia, menoxenia, dysmenorrhea, amenorrhea, and pyocutaneous disease swelling and pain.
Peach kernel: has effects of promoting blood circulation, removing blood stasis, loosening bowel to relieve constipation, relieving cough and asthma, and can be used for treating dysmenorrhea due to amenorrhea, abdominal mass, pulmonary abscess, acute appendicitis, traumatic injury, constipation due to intestinal dryness, cough and asthma.
Cortex moutan radicis): has effects of clearing heat, cooling blood, promoting blood circulation, and removing blood stasis, and can be used for treating toxic heat, speckle, hematemesis, epistaxis, carbuncle, swelling, pyocutaneous disease, amenorrhea, dysmenorrhea, traumatic injury, etc.
Chinese yam: has effects in invigorating qi, nourishing yin, invigorating spleen, invigorating stomach, tonifying kidney, supporting yang, and improving digestion, and can be used for treating yin deficiency, internal heat, spleen deficiency, excessive dampness, edema, etc.
Chinese magnoliavine fruit: has effects in astringing, promoting astringency, invigorating qi, promoting salivation, invigorating kidney, and tranquilizing mind, and can be used for treating insomnia, anxiety, cough, etc.
After the scheme is adopted, the following beneficial effects are realized:
1. the formula for reducing blood sugar and soothing heart for treating diabetic myocardial injury is provided in the scheme, wherein ginseng, dwarf lilyturf tuber and Chinese magnoliavine fruit are components of Shengmai powder and are named formulas with the effects of nourishing yin, tonifying qi, promoting the production of body fluid and nourishing heart; the dogwood and the yam are components of the left-return pill, and have the effects of nourishing kidney, replenishing yin, nourishing yin and suppressing yang; carapax Trionycis, radix et rhizoma Rhei, semen Persicae and cortex moutan are the main ingredients of carapax Trionycis decoction pill, and are effective in nourishing kidney yin, softening hard mass, resolving hard mass, removing food stagnation, clearing deficiency heat, quenching thirst, and relieving chest obstruction with yin deficiency, dryness heat, and removing blood stasis; adding radix astragali, and supplementing qi, strengthening body resistance, invigorating qi, and promoting blood production to achieve the effects of eliminating toxin and removing toxic substances; adding Coptidis rhizoma to match with radix et rhizoma Rhei, clearing heat and detoxicating, eliminating dampness and eliminating turbid pathogen; dan Shen is added to activate blood and dissipate blood stasis together with Tao ren and Dan Pi. The whole formula has the effects of tonifying and strengthening body resistance and eliminating pathogenic factors, and has the effects of nourishing yin and supplementing qi, activating blood and detoxicating, softening hardness and resolving hard mass and removing blood stasis.
2. Not only can regulate myocardial energy metabolism and improve myocardial remodeling, thereby improving cardiac function, but also has no obvious adverse reaction and better safety.
3. The hypoglycemic heart-soothing formula for treating the diabetic myocardial injury provided by the scheme can have lasting curative effect after being taken for a long time, and can comprehensively regulate various aspects of the body so as to achieve the purpose of health.
Drawings
FIG. 1 is a flow chart of an embodiment of a hypoglycemic heart soothing formulation for diabetic myocardial damage according to the present application.
Detailed Description
Embodiments of the present application are described in detail below, examples of which are illustrated in the accompanying drawings, wherein like or similar reference numerals refer to like or similar elements or elements having like or similar functions throughout. The embodiments described below by referring to the drawings are illustrative only and are not to be construed as limiting the application.
In the description of the present application, it should be understood that the terms "longitudinal," "transverse," "vertical," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," and the like indicate or are based on the orientation or positional relationship shown in the drawings, merely to facilitate description of the application and to simplify the description, and do not indicate or imply that the devices or elements referred to must have a particular orientation, be configured and operated in a particular orientation, and thus should not be construed as limiting the application.
In the description of the present application, unless otherwise specified and defined, it should be noted that the terms "mounted," "connected," and "coupled" are to be construed broadly, and may be, for example, mechanical or electrical, or may be in communication with each other between two elements, directly or indirectly through intermediaries, as would be understood by those skilled in the art, in view of the specific meaning of the terms described above.
The following is a further detailed description of the embodiments:
reference numerals in the drawings of the specification include: 1. 2, 3, 4, 5, 6, 7, 8, 9, 10.
Example 1, substantially as shown in figure 1: a hypoglycemic heart-soothing formula applied to diabetic myocardial injury comprises the following components in parts by weight: 10-20g of turtle shell, 10-20g of ginseng, 10-20g of astragalus, 10-20g of dwarf lilyturf tuber, 15-25g of dogwood, 10-20g of radix rehmanniae, 10-20g of rhubarb, 5-15g of coptis chinensis, 20-30g of red sage root, 7-17g of peach kernel, 10-20g of tree peony bark, 15-25g of Chinese yam and 5-15g of Chinese magnoliavine fruit.
Embodiment 2 differs from the above embodiment in that: comprises the following components in parts by weight: 10g of turtle shell, 10g of ginseng, 10g of astragalus, 10g of dwarf lilyturf tuber, 15g of dogwood, 10g of radix rehmanniae, 10g of rhubarb, 5g of coptis chinensis, 20g of red sage root, 7g of peach kernel, 10g of moutan bark, 15g of Chinese yam and 5g of shizandra berry.
Embodiment 3 differs from the above embodiment in that: comprises the following components in parts by weight: 15g of turtle shell, 15g of ginseng, 15g of astragalus, 15g of dwarf lilyturf tuber, 20g of dogwood, 15g of dried rehmannia root, 15g of rhubarb, 10g of coptis chinensis, 25g of red sage root, 12g of peach kernel, 15g of moutan bark, 20g of Chinese yam and 10g of shizandra berry.
Embodiment 4 differs from the above embodiment in that: 20g of turtle shell, 20g of ginseng, 20g of astragalus, 20g of dwarf lilyturf tuber, 25g of dogwood, 20g of dried rehmannia root, 20g of rhubarb, 15g of coptis chinensis, 30g of red sage root, 17g of peach kernel, 20g of moutan bark, 25g of Chinese yam and 15g of shizandra berry.
Embodiment 5 differs from the above embodiment in that: is prepared by the following method:
step one: selecting materials, selecting mud sand and foreign matters of the medicinal materials, and weighing the medicinal materials according to any weight of the examples 1-4;
step two: grinding all the medicinal materials respectively;
step three: mixing the medicinal material powder ground in the second step, and uniformly stirring;
step four: sterilizing, wherein radiation sterilization is used for carrying out radiation sterilization on all the prepared medicines to be packaged.
The weight of the raw materials in the examples was selected according to any one of examples 1 to 4.
The specific implementation process is as follows:
step one: according to any one of the embodiments 1-4, carapax Trionycis, radix Ginseng, radix astragali, radix Ophiopogonis, fructus Corni, radix rehmanniae, radix Et rhizoma Rhei, rhizoma Coptidis, radix Salviae Miltiorrhizae, semen Persicae, cortex moutan, rhizoma Dioscoreae, and fructus Schisandrae chinensis are weighed, and the silt and foreign matter of the materials are carefully selected.
Step two: grinding all the medicinal materials respectively, wherein the turtle shell, the dogwood, the radix rehmanniae, the red sage root, the peach kernel, the moutan bark and the yam are extracted by a conventional water extraction process to prepare extract fine powder; grinding Ginseng radix, radix astragali, radix Ophiopogonis, radix et rhizoma Rhei, coptidis rhizoma and fructus Schisandrae respectively into fine powder.
Step three: mixing the medicinal material powder ground in the second step, and uniformly stirring; can be made into granule, powder, capsule, watered pill, tablet, etc. according to requirement;
step four: sterilizing, wherein radiation sterilization is used for carrying out radiation sterilization on all the prepared medicines to be packaged.
Through clinical experiments, the better beneficial technical effects are obtained, and partial clinical data are as follows:
1. case selection: 80 patients with inpatient and outpatient diabetes mellitus combined with NYHA cardiac function grading type II-III diabetes mellitus myocardial injury are divided into an observation group and a control group according to random numbers generated by a computer, 40 patients in each group are respectively provided with two groups of sex, age, body Mass Index (BMI), diabetes course, myocardial injury course, heart rate, systolic pressure, diastolic and cardiac function grade and the like, and the differences are not statistically significant (P is more than 0.05; as shown in a data comparison table of two groups of patients in table 1), so that the two groups of data are balanced and comparable.
Table 1 two sets of patient data comparison tables
2. The treatment method comprises the following steps: both groups of patients treated were glycemic control according to the guidelines for prevention and treatment of type 2 diabetes in China (version 2013) and cardiac injury according to the guidelines for diagnosis and treatment of dilated cardiomyopathy (2020).
The administration method of the control group comprises the following steps: 20mg of gliquidone (purchased from Beijing Wanhui double crane pharmaceutical industry Co., ltd.) is taken once daily; benazepril (purchased from beijing nohua pharmaceutical limited) 10mg once daily.
The observation group takes the hypoglycemic and comfortable heart prescription applied to the diabetic myocardial injury on the basis of the conventional treatment, 1 time a day.
The treatment course is 2 months, and other concomitant diseases can be treated appropriately according to the situation, such as combined infection for anti-infection treatment, but other traditional Chinese medicines with effects of supplementing qi and nourishing yin and activating blood circulation to dissipate blood stasis are forbidden.
3. Curative effect comparison table:
4. conclusion: the effective rate of the observation group treated by the formula of the application combined with conventional treatment is higher than that of the control group treated by western medicines, and the adverse reaction ratio in the control group is higher than that in the observation group, and the adverse reaction comprises various symptoms such as drug allergy, somnolence, dizziness, hypodynamia and the like.
The research results show that: the formula of the application can reduce the ventricular filling pressure and reduce the morphological index LVEDV in combination with conventional treatment, thereby reducing the ventricular secretion BNP, effectively reducing the insulin resistance of diabetics, controlling the blood sugar, correcting lipid metabolism disorder, regulating myocardial energy metabolism and improving myocardial reconstruction, thereby improving cardiac function, having no obvious adverse reaction and having better safety.
The foregoing is merely exemplary of the present application and the specific structures and/or characteristics of the present application that are well known in the art have not been described in detail herein. It should be noted that modifications and improvements can be made by those skilled in the art without departing from the structure of the present application, and these should also be considered as the scope of the present application, which does not affect the effect of the implementation of the present application and the utility of the patent. The protection scope of the present application is subject to the content of the claims, and the description of the specific embodiments and the like in the specification can be used for explaining the content of the claims.
Claims (6)
1. A hypoglycemic heart-soothing formula applied to diabetic myocardial injury is characterized in that: comprises the following components in parts by weight: 10-20g of turtle shell, 10-20g of ginseng, 10-20g of astragalus, 10-20g of dwarf lilyturf tuber, 15-25g of dogwood, 10-20g of radix rehmanniae, 10-20g of rhubarb, 5-15g of coptis chinensis, 20-30g of red sage root, 7-17g of peach kernel, 10-20g of tree peony bark, 15-25g of Chinese yam and 5-15g of Chinese magnoliavine fruit.
2. The hypoglycemic heart soothing formula for treating diabetic myocardial injury according to claim 1, wherein: comprises the following components in parts by weight: 10g of turtle shell, 10g of ginseng, 10g of astragalus, 10g of dwarf lilyturf tuber, 15g of dogwood, 10g of radix rehmanniae, 10g of rhubarb, 5g of coptis chinensis, 20g of red sage root, 7g of peach kernel, 10g of moutan bark, 15g of Chinese yam and 5g of shizandra berry.
3. The hypoglycemic heart soothing formula for treating diabetic myocardial injury according to claim 2, wherein: comprises the following components in parts by weight: 15g of turtle shell, 15g of ginseng, 15g of astragalus, 15g of dwarf lilyturf tuber, 20g of dogwood, 15g of dried rehmannia root, 15g of rhubarb, 10g of coptis chinensis, 25g of red sage root, 12g of peach kernel, 15g of moutan bark, 20g of Chinese yam and 10g of shizandra berry.
4. The hypoglycemic heart soothing formulation for diabetic myocardial injury according to claim 3, wherein: comprises the following components in parts by weight: 20g of turtle shell, 20g of ginseng, 20g of astragalus, 20g of dwarf lilyturf tuber, 25g of dogwood, 20g of dried rehmannia root, 20g of rhubarb, 15g of coptis chinensis, 30g of red sage root, 17g of peach kernel, 20g of moutan bark, 25g of Chinese yam and 15g of shizandra berry.
5. The hypoglycemic heart soothing formula for treating diabetic myocardial injury according to claim 4, wherein: is prepared by the following method:
step one: selecting materials, selecting mud sand and foreign matters of the medicinal materials, and weighing the medicinal materials according to any weight of the examples 1-4;
step two: grinding all the medicinal materials respectively;
step three: mixing the medicinal material powder ground in the second step, and uniformly stirring;
step four: sterilizing, wherein radiation sterilization is used for carrying out radiation sterilization on all the prepared medicines to be packaged.
6. The hypoglycemic heart soothing formulation for diabetic myocardial injury according to claim 5, wherein: the grinding medicinal materials in the steps are as follows: extracting carapax Trionycis, corni fructus, radix rehmanniae, saviae Miltiorrhizae radix, semen Persicae, cortex moutan and rhizoma Dioscoreae with water, and making into extract fine powder; grinding Ginseng radix, radix astragali, radix Ophiopogonis, radix et rhizoma Rhei, coptidis rhizoma and fructus Schisandrae respectively into fine powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310448739.8A CN116570679A (en) | 2023-04-24 | 2023-04-24 | Blood sugar reducing and heart soothing formula applied to diabetic myocardial injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310448739.8A CN116570679A (en) | 2023-04-24 | 2023-04-24 | Blood sugar reducing and heart soothing formula applied to diabetic myocardial injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116570679A true CN116570679A (en) | 2023-08-11 |
Family
ID=87533205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310448739.8A Pending CN116570679A (en) | 2023-04-24 | 2023-04-24 | Blood sugar reducing and heart soothing formula applied to diabetic myocardial injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116570679A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101091765A (en) * | 2007-06-08 | 2007-12-26 | 余仁生国际有限公司 | Medicinal comsns-and usage for preventing and treating diabets mellitus |
| CN102225149A (en) * | 2007-07-27 | 2011-10-26 | 北京亚东生物制药有限公司 | Traditional Chinese medicine compound for treating diabetes and preparation method thereof |
-
2023
- 2023-04-24 CN CN202310448739.8A patent/CN116570679A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101091765A (en) * | 2007-06-08 | 2007-12-26 | 余仁生国际有限公司 | Medicinal comsns-and usage for preventing and treating diabets mellitus |
| CN102225149A (en) * | 2007-07-27 | 2011-10-26 | 北京亚东生物制药有限公司 | Traditional Chinese medicine compound for treating diabetes and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 宋君;何关义;: "参芪方剂加减治疗2型糖尿病大血管病变临床研究", 内蒙古中医药, no. 18, 30 June 2014 (2014-06-30), pages 4 - 5 * |
| 殷丽平;谢春光;张红敏;刘桠;: "参芪复方对自发性糖尿病GK大鼠心肌TGF-β_1表达的影响", 福建中医药, no. 03, 28 June 2009 (2009-06-28), pages 38 - 40 * |
| 谢毅强;谢春光;张红敏;: "参芪复方对自发性糖尿病大鼠血管内皮保护的作用机制", 中华中医药杂志, no. 03, 1 March 2008 (2008-03-01), pages 253 - 256 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103623341A (en) | Drug for treating hypertension and cardiovascular and cerebrovascular diseases caused by hypertension | |
| CN101947284A (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN104013849A (en) | Traditional Chinese medicinal composition for treating hypertension and preparation method thereof | |
| CN103768407B (en) | A kind of hypoglycemic compound capsule and preparation method thereof | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN103989970B (en) | A kind of Chinese medicine composition treating hypertension | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN103735843A (en) | Medicine composition for treating diabetes | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN108355055A (en) | A kind of pharmaceutical composition for treating hypertension | |
| CN116570679A (en) | Blood sugar reducing and heart soothing formula applied to diabetic myocardial injury | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN102293855A (en) | Chinese medicinal composition for treating speech and kidney deficiency diabetic nephropathy, and preparation method and application thereof | |
| CN105055967A (en) | Compound health care product having auxiliary blood sugar reducing function and preparation method | |
| CN107669910B (en) | Pharmaceutical composition for treating atherosclerosis | |
| CN105343688A (en) | Medicine composition for treating myocardial infarction and application thereof | |
| CN101987188B (en) | Biological Chinese patent drug for preventing and treating hyperlipoidemia | |
| CN106668431B (en) | A Chinese medicinal composition with effects of warming kidney and invigorating qi, and its preparation method and application | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN106581425A (en) | Pharmaceutical composition for treating | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN108392583A (en) | A kind of Chinese medicine preparation for treating diabetic nephropathy | |
| CN100571739C (en) | Herbal mixture of treatment cardiovascular disease and preparation method thereof | |
| CN101104033A (en) | Traditional Chinese medicinal preparation for treating Parkinson's disease and preparing process thereof | |
| CN105213774A (en) | A kind of pharmaceutical composition for the treatment of chronic heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |